Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease

Neuroscience Letters

Volumn 595, Issue , 2015, Pages 116-121

  Peng, Mao ^a,b,c,d   Jia, Jianping ^a,b,c,d   Qin, Wei ^b,c,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c Beijing Key Laboratory of Geriatric Cognitive Disorders   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Alzheimer disease; Biomarker; Gelsolin; Matrix metalloproteinase 3; Plasma

Indexed keywords

GELSOLIN; STROMELYSIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; ASSESSMENT OF HUMANS; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL DEMENTIA RATING SCALE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEX RATIO; BLOOD; CASE CONTROL STUDY; MENTAL HEALTH; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GELSOLIN; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MENTAL STATUS SCHEDULE; SENSITIVITY AND SPECIFICITY;

EID: 84927934378     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.04.014     Document Type: Article

References (26)

1. O'Bryant S.E., Xiao G., Barber R., Reisch J., Doody R., Fairchild T., Adams P., Waring S., Diaz-Arrastia R., Texas Alzheimer's research Consortium A serum protein-based algorithm for the detection of Alzheimer disease. Arch. Neurol. 2010, 67:1077-1081.
2. Snyder H.M., Carrillo M.C., Grodstein F., Henriksen K., Jeromin A., Lovestone S., Mielke M.M., O'Bryant S., Sarasa M., Sjogren M., Soares H., Teeling J., Trushina E., Ward M., West T., Bain L.J., Shineman D.W., Weiner M., Fillit H.M. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2014, 10:109-114.
3. Li G.H., Arora P.D., Chen Y., McCulloch C.A., Liu P. Multifunctional roles of gelsolin in health and diseases. Med. Res. Rev. 2012, 32:999-1025.
4. Ray I., Chauhan A., Wegiel J., Chauhan V.P. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res. 2000, 853:344-351.
5. Hirko A.C., Meyer E.M., King M.A., Hughes J.A. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol. Ther. 2007, 15:1623-1629.
6. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 2003, 23:29-33.
7. Yang W., Chauhan A., Mehta S., Mehta P., Gu F., Chauhan V. Trichostatin A increases the levels of plasma gelsolin and amyloid beta-protein in a transgenic mouse model of Alzheimer's disease. Life Sci. 2014, 99:31-36.
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
9. Guntert A., Campbell J., Saleem M., O'Brien D.P., Thompson A.J., Byers H.L., Ward M.A., Lovestone S. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J. Alzheimers Dis. 2010, 21:585-596.
10. Park S.M., Hwang I.K., Kim S.Y., Lee S.J., Park K.S., Lee S.T. Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics 2006, 6:1192-1199.
11. Okada Y., Nagase H., Harris E.D. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components purification and characterization. J. Biol. Chem. 1986, 261:14245-14255.
12. Mattsson N., Insel P., Nosheny R., Trojanowski J.Q., Shaw L.M., Jack C.R., Tosun D., Weiner M. Alzheimer's disease neuroimaging initiative. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol. Aging 2014, 35:614-622.
13. Mroczko B., Groblewska M., Zboch M., Kulczynska A., Koper O.M., Szmitkowski M., Kornhuber J., Lewczuk P. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. J. Alzheimers Dis. 2014, 40:351-357.
14. Stomrud E., Bjorkqvist M., Janciauskiene S., Minthon L., Hansson O. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res. Ther. 2010, 2:20.
15. Hanzel C.E., Iulita M.F., Eyjolfsdottir H., Hjorth E., Schultzberg M., Eriksdotter M., Cuello A.C. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. J. Alzheimers Dis. 2014, 40:667-678.
16. Horstmann S., Budig L., Gardner H., Koziol J., Deuschle M., Schilling C., Wagner S. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int. Psychogeriatr. 2010, 22:966-972.
17. Wang X.X., Tan M.S., Yu J.T., Tan L. Matrix metalloproteinases and their multiple roles in Alzheimer's disease. Biomed. Res. Int. 2014, 2014:908636.
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
19. Tsai M.S., Tangalos E.G., Petersen R.C., Smith G.E., Schaid D.J., Kokmen E., Ivnik R.J., Thibodeau S.N. Apolipoprotein E: risk factor for Alzheimer disease. Am. J. Hum. Genet. 1994, 54:643-649.
20. Kwiatkowski D.J., Mehl R., Yin H.L. Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J. Cell Biol. 1988, 106:375-384.
21. Chauhan V.P., Ray I., Chauhan A., Wisniewski H.M. Binding of gelsolin a secretory protein to amyloid beta-protein. Biochem. Biophys. Res. Commun. 1999, 258:241-246.
22. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 2006, 281:17670-17680.
23. Yin K.J., Cirrito J.R., Yan P., Hu X., Xiao Q., Pan X., Bateman R., Song H., Hsu F.F., Turk J., Xu J., Hsu C.Y., Mills J.C., Holtzman D.M., Lee J.M. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 2006, 26:10939-10948.
24. Deb S., Wenjun Zhang J., Gottschall P.E. Beta-amyloid induces the production of active matrix-degrading proteases in cultured rat astrocytes. Brain Res. 2003, 970:205-213.
25. Reitz C., van Rooij F.J., Soares H.D., de Maat M.P., Hofman A., Witteman J.C., Breteler M.M. Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam Study. Neurobiol. Aging 2010, 31:715-718.
26. Song F., Poljak A., Valenzuela M., Mayeux R., Smythe P.S., Sachdev G.A. Meta-analysis of plasma amyloid- levels in Alzheimer's Disease. J. Alzheimer's Dis. 2011, 26:365-375.